Related Experiment Video
Updated: Feb 4, 2026

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel
Published on: May 14, 2018
Paclitaxel drives TREM2+ macrophage expansion underlying its inferior therapeutic efficacy compared to Nab-paclitaxel
Yuqi Xing1,2,3, Ruiqi Zhong4,5, Qianchen Li1,2,3
1School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Abstract:
Paclitaxel and nab-paclitaxel differ in therapeutic efficacy and modulation of the tumor immune microenvironment, yet the molecular basis remains poorly defined. Here, based on a meta-analysis, we first show that treatment with nab-paclitaxel results in a higher overall response rate and pathological complete response compared to paclitaxel in female patients with breast cancer. Notably, TREM2 expression in macrophages is elevated in primary tumors of paclitaxel- but not nab-paclitaxel-treated female patients. In metastatic breast cancer, TREM2+ macrophage infiltration is increased in primary tumors. In breast cancer models in female mice, paclitaxel, but not nab-paclitaxel, promotes lung metastasis by recruiting TREM2+ macrophages to primary tumors. Mechanistically, paclitaxel enhances the ATF3-FGF2 axis in breast cancer cells; secreted FGF2 activates the EGR1-TREM2-EMT cytokine axis in macrophages. Genetic ablation of Trem2 or pharmacologic targeting with antisense oligonucleotides suppress paclitaxel-induced breast cancer lung metastasis in vivo. Collectively, our findings demonstrate that paclitaxel, but not nab-paclitaxel, stimulates TREM2 expression and expands TREM2+ macrophages, suggesting that TREM2 targeting could enhance paclitaxel efficacy while limiting metastasis.
Insights
Paclitaxel, not nab-paclitaxel, increases TREM2+ macrophages, promoting breast cancer lung metastasis. Targeting TREM2 may improve paclitaxel efficacy and reduce metastasis.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Paclitaxel and nab-paclitaxel exhibit different clinical efficacy and immune microenvironment effects.
- The molecular mechanisms underlying these differences are not fully understood.
Purpose of the Study:
- To investigate the differential effects of paclitaxel and nab-paclitaxel on breast cancer progression and the tumor immune microenvironment.
- To elucidate the role of TREM2 (triggering receptor expressed on myeloid cells 2) and associated macrophages in paclitaxel-induced metastasis.
Main Methods:
- Meta-analysis of patient data.
- In vivo studies using female mouse models of breast cancer.
- Molecular analyses including gene expression and cytokine axis investigation.
- Genetic ablation and antisense oligonucleotide targeting of TREM2.
Main Results:
- Nab-paclitaxel showed higher response rates than paclitaxel in female breast cancer patients.
- Paclitaxel, unlike nab-paclitaxel, elevated TREM2 expression in tumor-associated macrophages.
- Paclitaxel promoted lung metastasis in mice by recruiting TREM2+ macrophages via the ATF3-FGF2 and EGR1-TREM2-EMT axes.
- TREM2 inhibition suppressed paclitaxel-driven metastasis.
Conclusions:
- Paclitaxel, but not nab-paclitaxel, stimulates TREM2 expression and expands TREM2+ macrophages.
- This expansion contributes to paclitaxel-induced breast cancer lung metastasis.
- Targeting TREM2 presents a potential strategy to enhance paclitaxel therapy and mitigate its metastatic potential.
More Related Videos
Related Concept Videos
Self-Efficacy
Energy to Drive Translocation
Generally, polypeptides are unfolded by two distinct...
Heat and Free Expansion
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Thermal Expansion
Comparing Copy Number Variations and SNPs
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...

